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Obesity is reaching epidemic worldwide and is risk factor for cardiovascular disease and type 2 diabetes. Although
plasma high density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) are inversely correlated to obesity, whether
HDLs have anti-obesity effect remains unclear until a recent study reporting the direct anti-obesity effect of apoA-I
and its mimetic peptide. However, the mechanism is not fully understood. Increasing adipose energy expenditure
through attainment of brown adipocyte phenotype in white adipose tissue is considered a potential strategy to
combat obesity. Specific inhibition of autophagy in adipose tissue is associated with reduced adiposity which is
attributed to the attainment of brown adipocyte phenotype in white adipose tissue and the increased energy
expenditure. HDL and apoA-I could activate PI3K-Akt-mTORC1 signaling which negatively regulates autophagy. The
links between HDL/apoA-I and autophagy brings a new understanding on the anti-obesity effect of HDL
and apoA-I.
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Obesity is the most common nutritional disorder and is
associated with important comorbidities such as dyslipi-
demia, atherosclerosis, type 2 diabetes and insulin resist-
ance [1]. Anti-obesity pharmacotherapy is a potentially
important adjunctive treatment to lifestyle modification.
Drugs used to induce weigh loss may act through redu-
cing appetite and increase satiety (e.g. sibutramine and
rimonabant), reduce the absorption of nutrients (e.g.
orlistat) [2]. Amongst the drugs marketed for weight loss
there have been many instances of market withdrawl
due to adverse events, leaving only orlistat approved for
long term use [3]. The selective cannabinoid 1-receptor
blocker Rimonabant, once considered as a promising
anti-obesity drug which could improve dyslipidemia
associated with the metabolic syndrome, including rais-
ing HDL and reducing TG, has been withdrawn recently
from the market because of psychiatric adverse events
[3-5]. Another problem with anti-obesity drugs is lack of* Correspondence: pengdq@hotmail.com
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Therefore, development of effective and safe drugs is an
area of intense clinical interest.
The well-established cardioprotective nature of high-
density lipoproteins (HDLs) has made them and their
main protein apolipoprotein A-I (apoA-I) popular tar-
gets for potential cardiovascular therapies. Current
HDL-based therapies including direct infusion of rHDL
and apoA-I mimetic peptides have exhibted abroad
beneficial effects aside from mediating cholesterol efflux
such as anti-inflammatory, anti-oxidative actions and
shown potential usefulness as therapy for diseases in-
volving chronic inflammation and oxidative stress [6].
One of the proatherogenic effects of obesity is attribut-
able to its accompanying dyslipidemia. The prominent
dyslipidemia in obesity is low high density lipoprotein
cholesterol (HDL-C) levels and apoA-I. Epidemiological
studies have shown a strong inverse correlation between
HDL-C, apoA-I and obesity, especially in individuals
with visceral obesity [7]. This inverse correlation was
originally attributed to the disturbed metabolism of
HDL and apoA-I in obesity status. But recent studiestral Ltd. This is an Open Access article distributed under the terms of the
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obesity. This article will focus on the updated under-
standing of the anti-obesity effect of HDL and apoA-I.
Anti-obesity effect of apoA-I
Obesity is defined medically as a state of increased body
weight, more specifically adipose tissue, or sufficient
magnitude to produce adverse health consequence [8].
As the body’s largest energy reservoir, adipose tissue
serves the primary function of lipid storage in the fed
state. In fasting state, fatty acid is released from the
breakdown of triglyceride (TG) into circulation for en-
ergy production [9]. Prolonged energy imbalance be-
tween energy intake and expenditure leads to an
increase in both fat cell size and fat cell number [10].
Large adipocytes especially adipocytes present in visceral
fat have a higher rate of lipolysis. It is known that obes-
ity clearly associates with increased circulating free fatty
acids (FFAs) and adipocytokines which not only initiate
adipose inflammation but also drive all aspects of meta-
bolic syndrome, including insulin resistance, dyslipide-
mia, and hypertension, eventually leading to increased
risk for cardiovascular diseases [1].
HDL is generally considered as a protective factor for
cardiovascular disease. In addition to the well known ef-
fect of mediating reverse cholesterol transport, it also
exerts other beneficial functions such as anti-oxidative,
anti-inflammatory and anti-thrombotic actions [11]. It’s
well known that obese individuals display lower plasma
levels of HDL-cholesterol and apoA-I, with HDL-
cholesterol levels associated with both degree and distri-
bution of obesity [7,8,12].
Previous findings that several polymorphrism in apoli-
poprotein A1(ApoA-I) gene have been associated with
obesity in Brazilian population and that body fat content
was increased in apoA-I null mice model lead to query
about the role apoA-I played in obesity development
[13,14]. Several recent studies aimed to answer this
question studied the role of apoA-I in regulating obesity
through two main lines of investigation: (1)overexpres-
sion of genes that encode apoA-I in mouse models; (2)
administration of apoA-I mimetics D-4F and L-4F, which
share structural and biological features of native apolipo-
protein A-I, to mimic increased plasma apoA-I level in
mouse models. Diet-induced obesity (DIB) was gener-
ated in apoA-I transgenic (ApoA-I-Tg) and wild type
mice by feeding high fat diet for three months. Although
both groups of mice had the same body weight gain and
food intake, the body fat content was significantly lower
in ApoA-I-Tg mice than the wild-type mice as evidenced
by reduced weight of epididymal and retroperitoneal fat
pat. Consistent with this result, in other studies, daily
administration of D-4F and L-4F in high fat diet fed
mice reduced weight gain and decreased obesityassociated hyperglycemia when compared with age-
matched vehicle-treated obese mice [15,16]. Taken together,
these observations implicated a potential anti-obesity effect
of apoA-I.
Up to date, there are several strategies for pharmaco-
therapy of obesity, including: (1) appetite suppression
through central stimulation of anorexigenic signals or
blocking orexigenic signals; (2) inhibition of nutrient di-
gestion and absorption through gastrointestinal mechan-
ism; (3) stimulation of fat mobilization and decreasing
triacylglycerol synthesis and deposition in fat depots; (4)
increase lipid oxidation or thermogenesis by uncoupling
fuel metabolism, thereby enhancing energy expenditure
[17]. In the above mentioned studies, the anti-obesity ef-
fect of apoA-I was not associated with a reduction of
food intake or increased locomotive movement. Investi-
gation into the metabolic profile confirmed enhanced
energy expenditure through increased respiratory ex-
change ratio with consistent increased expression of
uncoupled protein 1 (UCP1) in brown adipose tissue
[16]. UCP1 expresses specifically in brown adipose tissue
and is responsible for detaching fatty acid oxidation
from the coupling to respiratory chain, resulting in
thermogenesis [18]. It has been demonstrated that
increased expression of UCP1 in brown adipocyte or ec-
topic expression of UCP1 in mouse or human skeletal
muscle and white adipocyte promotes fatty acid oxida-
tion and resistance to obesity [19]. Intriguingly, ApoA-I
gene overexpression and D-4F treatment lead to signifi-
cantly increased expression of UCP1 in brown adipose
tissue [16]. Therefore, UCP1 is probably one of the tar-
get genes regulated by apoA-I in brown fat, and such
regulation might contribute to the increase of energy ex-
penditure observed in apoA-I over-expression and mi-
metic peptide treated mice. However, the mechanism
underlying the anti-obesity effect of apoA-I remains to
be further elucidated.
Autophagy and obesity
Phenotype transition from WAT to BAT
Adipose tissue contains two distinct types of fat cells,
white and brown. The balance between white and brown
adipose tissue (BAT) is a factor that determines obesity.
White fat cells are specialized for the storage of chemical
energy as triglycerides, while brown fat cells have very
limited ability to store lipid and serve the primary func-
tion of dissipating chemical energy through adaptive
thermogenesis [20]. Since brown adipocyte is more oxi-
dative, BAT is generally considered as an organ counter-
acting obesity. Generally, proneness to obesity and
metabolic disease correlates with decreased BAT activity,
whereas resistance to obesity correlates with increased
BAT function or the induction of brown adipocyte-like
gene expression in white adipose tissue [21-27].
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ant only in small mammals such as rodent because in
human, BAT was previously thought to disappear soon
after birth [20]. Not until recent findings of presence of
substantial amounts of metabolically active brown adi-
pose in healthy adult human that the importance of
BAT in metabolism has been recognized and that the
speculation as to whether controlled recruitment of
brown adipocyte would be a potential strategy to combat
obesity has been raised [21,28-31].
Ample evidences support some plasticity exists be-
tween white and brown adipocyte. In mice and rats, ex-
posure to cold or β-adrenergic agonists induces the
appearance of brown adipocyte in traditional white fat
pats, which originate differently from the classic brown
adipocyte that develop before birth because these newly
formed brown adipocyte did not express the YFP re-
porter gene, which was conspicuously expressed in the
interscapular brown fat cells from the same mice [32-
35]. Similarly, in human, working in the cold
temperature could induce occurrence of brown adipose
tissue in outdoor workers [36]. Some pathological states
such as pheochromocytoma, hibernoma, and diseases in-
volving chronic hypoxia, Chagas’ disease, Duchenne dys-
trophy and cancers, are known to stimulate BAT
proliferation in white pats [37]. These evidences support
the possibility that under certain conditions,cell with the
morphology and molecular phenotype of brown fat can
be induced in WAT. In addition, given that BAT and
WAT are both present in various adipose tissue depots
in human, attainment of a brown adipocyte cell pheno-
type in white adipocyte may be a potential strategy for
combating obesity.
Autophagy regulate obesity through phenotype
transition
Autophagy, defined as a highly regulated process involv-
ing the bulk degradation of cytoplasmic macromolecules
and organelles in mammalian cells via the lysosomal sys-
tem, plays a housekeeping role in removing misfolded or
aggregated proteins, clearing damaged organelles, elim-
inating intracellular pathogens, and balancing sources of
energy at critical times in development and in response
to nutrient stress [38,39]. As a survival mechanism, dys-
regulated autophagy has been linked to many human
pathophysiologies, such as cancer, myopathies, neurode-
generation, heart and liver diseases [40]. Interestingly,
recent studies revealed that autophagy was upregulated
in obese individuals, as evidenced by increased expres-
sion of autophagy gene Atg5, LC3A, and LC3B as well
as elevated autophagic flux in omental and subcutaneous
adipose tissue [41]. Consistent with this conclusion,
other group reported that autophagy was strongly up-
regulated in patient with diagnosis of Type 2 diabetes(T2D) and overweight [42]. This relationship between
increased autophagy and obesity lead to a question that
what is the role autophagy play in the state of obesity.
On the one hand, excess lipid storage in hypertrophied
adipocyte leads to increased endocytoplasmic reticulum
(ER) activity, which ultimately overwhelms the capacity
of ER to properly fold nascent protein, therefore causing
ER stress and subsequent oxidative stress in the mito-
chondria, FFA release and proinflammatory state of adi-
poctye, which all impinge on mTOR and induce
autophagy [43]. In this sense, activated autophagy may
serve as a protective mechanism necessary for cell sur-
vival in the challenging environment that develops in
adipose tissue. On the other hand, increased autophagy
possibly signifies a process underlying cell death of
hypertrophied adipocyte [44].
To further elucidate the role of autophagy in the state
of obesity, recent studies used knockout mice model
with adipose tissue specific deletion of autophagy-related
gene Atg7 and Atg5 respectively. The Autophagy-related
gene knockout mice exhibited a metabolic favorable
phenotype. The mutant mice were slimmer with
increased insulin sensitivity and showed resistance to
high-fat-diet induced obesity compared with wide-type
mice. The mutant mice contain only 20% of the mass of
WAT found in wild-type mice [40,45,46]. Consistent
with this finding, in vitro studies using cell line preadi-
poctye 3T3-L1 and primary MEFs showed that autop-
hagy inhibition through Atg7 knockout or 3-MA
treatment blocked adipocyte differentiation [9]. Thus, it
seems that the metabolic favorable phenotype generated
in Atg7/Atg5 knockout mice may result from a blocking
in white adipocyte differentiaton which leads to a failure
of these cells to accumulate lipid. However, the
decreased serum free fatty acids and the absence of ac-
cumulation of excess lipid in nonadipose organs such as
liver and heart in mutant mice did not support this
proposition. Because WAT served as body’s main reser-
voir of lipids, if the WAT capacity of lipid storage was
simply blocked without any increased energy expend-
iture, detrimental elevation of serum FFA and ectopic
lipid deposition would occur. Actually, what’s interesting
in those studies was that most of the mutant white adi-
pocyte showed some characteristics of brown adipocytes.
They were smaller, multilocular and contain more mito-
chondria. These cells also exhibited altered fatty acid
metabolism with increased rates of β-oxidation and
reduced rates of hormone-induced lipolysis. In addition,
brown adipocyte specifically expressed UCP1 was found
in WAT of Atg7-knockout mice [45]. Former studies
have demonstrated that exogenous overexpression of
PGC-1α, a critical mediator of brown fat differentiation,
induced the development of features of brown fat in
WAT [47]. In autophagy-related gene-knockout mice,
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autophagy induced brown-like adipocyte in WAT may
either through promoting progenitor cell shutting into
the pathway of brown adipocyte differentiation or alter-
ing adipocyte transdifferentiation by promoting the con-
version of WAT into BAT or blocking the reverse
process. Since recent evidence support that WAT and
BAT have different precursors and that in the knockout
studies, younger mice (3 weeks) failed to show the
phenotypic change that was observed in older mice (12
weeks), it is most likely that the phenotypic changes oc-
curred after original WAT formation and was attributed
to a phenotype transition from “white to brown” [48].
As regard to how loss of autophagy mediated this
phenotypic transition process, it has been known that in
rodent, BAT and WAT expressed pre- and post-natal re-
spectively [49]. In human, recent studies demonstrated a
transient expression of UCP1 during adipogenesis of adi-
pocyte derived stem cells (ADSCs), which indicate the
possibility that ADSC pass through a brown adipocyte-
like stage while differentiating into adipocyte [50].
Therefore, autophagy may be critical for removal and
degradation of excessive mitochondria or proteins which
represent features of brown adipocyte during adiopogen-
esis. Downregulated autophagy in preadipocyte altered
the normal process of adipocyte differentiation and
resulted in adipocyte resembling brown adipocyte which
has increased ability of energy consumption (Figure 1).Figure 1 Autophagy regulated obesity through phenotype change. L
process to white adipocyte and resulted in “brown-like” adipocyte, which w
Metabolically, it had increased energy consumption through free fatty acid
increased insulin sensitivity.Regulation of autophagy
One of the major roles of autophagy is to serve as a cel-
lular adaptive reaction in order to sustain the internal
organization in the case of insufficient external nutrient
supply or augmented energy demands through digesting
their own interior. On the one hand, autophagy needs to
be upregulated under nutrient restriction. On the other
hand, cells have to avoid excessive and enduring self-di-
gestion. In order to keep the delicate balance between
external energy and nutrient supply and internal con-
sumption, complex regulatory network that sense the
environmental change is required.
The nutrient sensing kinase mTORC1 is well known
to negatively regulate the autophagic machinery. Diverse
external signals such as growth factor, amino acids, nor-
moxia, or high energy levels all activate mTORC1 and
result in the inhibition of autophagy [51-53]. mTORC1
inhibition, as resulting from rapamycin treatment was
surposed to resulted in induction of autophagy. In mam-
malian cells, however, rapamycin treatment failed to in-
duce autophagy as observed in yeast. This discrepancy is
attributed to the rapamycin-resistant function of
mTORC1. Although rapamycin fully inhibits mTORC1-
dependent phosphorylation of S6K1, it only partially
inhibits phosphorylation of other known mTORC1 sub-
strate [54]. As a consequence, some mTORC1
dependent function such as autophagy is left unaffected
by rapamycin. Instead, complete inhibition of mTORC1oss of autophagy in preadipocyte altered the normal differentiation
as smaller with multilocular lipid droplet and more mitochondria.
β-oxidation with consequently reduced lipid storage, less fat mass and
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could induce autophagy in mammalian cells [55]. In the
obesity status, whether the activity of mTORC1 is aug-
mented or attenuated is in debate. Previous studies using
high fat induce obesity mice model demonstrated
increased phosphorylation of mTORC1 substrate S6K1
in adipose tissue, which might indicate hyperactivity of
mTORC1 [56]. However, as mentioned above, S6K1
phosphorylation does not represent the full function of
mTORC1 activity. In addition, other study showed atte-
nuated mTORC1 signaling along with affected down-
stream effects of mTORC1 signaling such as upregulated
autophagy and impaired mitochondria in human adipo-
cyte from obese patient with Type 2 Diabetes [42]. The
reason for these discrepant results is still not clear. It is
possible that the degree of obesity or whether insulin re-
sistance exists may account for it.
AMP-activated protein kinase (AMPK) is regarded as
the main energy-sensing enzyme that promotes all var-
ieties of catabolic pathways and blocks several anabolic
pathways [57]. AMPK has been well known to be linked
to regulation of autophagy. Under energy-lower condi-
tions, AMPK is activated, leading to autophagy induc-
tion [58]. Activated AMPK was thought to induce
autophagy both directly through its action on autophagy
initiator UIK1 (unc-51-like kinase 1) and indirectly
through its action on mTORC1. In case of alarming en-
ergy states, AMPK could counteract the mTORC1-
mediated repression on autophagy by at least two
mechanisms through its action on TSC2 or Raptor
[52,59]. In the state of obesity where energy intake
exceeds energy consumption, AMPK activity in adipose
tissue is decreased. However, whether this change in
AMPK signaling alone under the situation of obesity is
sufficient to affect autophagy rate is still not clear.
Sterol depletion, a selective form of nutrient depletion,
has been reported to induce autophagy. Recently, it was
suggested that in the situation of sterol limitation, apart
from the de novo synthesis and receptor-mediated up-
take pathway, cell could recycle cytoplasmic lipid droplet
as a source of cholesterol through the process of autop-
hagy [60]. Sterol regulatory element-binding protein 2
(SREBP2), which preferentially controls expression of
many cholesterogenic genes, is attributable to the sens-
ing of cholesterol requirement and act as a feedback
mechanism to maintain sterol homeostasis [61]. Recent
study showed that SREBP2 directly activated autophagy
genes during sterol depletion. Besides, SREBP-2 knock-
down in the condition of cholesterol depletion decreased
autophagosome formation and lipid droplet association
of autophagosome related protein LC3 [62]. Numerous
studies have proposed that the dilution in membrane
cholesterol in hypertrophied adipocye may be sensed as
true cholesterol depletion. SREBP2 that is sensitive tomembrane cholesterol depletion is selectively activated
in hypertrophied adipocyte in several obesity mice mod-
els [63]. Although SREBP2 may not be a general regula-
tor of autophagy taken that many other situations that
trigger autophagy are independent of cell lipid metabol-
ism and that changes in gene expression is not essential
for the rapid initiation of autophagy, it is reasonable to
presume that genes involved in the induction of autop-
hagy be activated in response to conditions where cell
cholesterol is limited through the regulation of SREBP2.
HDL and autophagy
HDL prevent autophagy
Taken that HDL and apoA-I are inversely correlated to
obesity and that apoA-I exhibits a direct anti-obesity ac-
tion, it is of great interest to answer the question
whether HDL/apoA-I could modulate adipocyte autop-
hagy. Under conditions of excessive nutrition such as
obesity, ER becomes stressed and results in activation of
the copying system, which is termed unfolding protein
response (UPR), in many metabolic tissues such as adi-
pose tissue. Autophagy is activated by UPR so that
unfolded and misfolded proteins could be degraded [64].
Recent studies reported that HDLs prevent ER stress in
human endothelial cells and pancreatic β cells by redu-
cing ER signaling and restoring protein folding and traf-
ficking [65-67]. Thus, it is reasonable to hypothesize that
HDLs may affect autophagy rate through alleviation of
ER stress under the situation when stimuli exists. Inter-
estingly, there is direct evidence showing that HDLs are
able to prevent autophagy triggered by ox-LDL in endo-
thelium [67]. Additionally, a large body of evidences
support that HDL could activate PI3K-Akt signaling [68-
71], a well identified upstream signaling of mTORC1
activation, which negatively regulate autophagy.
HDL activated PI3K signaling
A major upstream signaling of mTORC1 is the phospha-
tidylinositol 3-kinase (PI3K) pathway. The binding of
growth factor or insulin to cell surface receptors acti-
vates PI3K, which converts the plasma membrane lipid
PIP2 to PIP3, subsequently recruits PDK1 and Akt to
the plasma. Following being phosphorylated by PDK1,
activated Akt positively regulates mTORC1 through
phosphorylation-dependent inhibition of TSC2 with
consequent autophagy inhibition [72].
Although numerous evidences showed HDL/apoA-I
actived PI3K-Akt pathway in different cell lines, the
underlying molecule mechanism still remains unclear.
Rising evidences suggested that SR-BI, which mediated
multiple antiatherogenic functions of HDL, was involved
in PI3K-Akt signaling activation in response to HDL
stimuli. Knock-down of SR-B1 by siRNA significantly
attenuated HDL induced PI3K-Akt-eNOS signaling and
Figure 2 Effect of HDL/apoA-I on autophagy in preadipocyte. HDL/apoA-I activated PI3K-Akt signaling pathway through SR-BI dependent
mechanism and/or S1P of HDL binding to S1P receptor. Activated Akt positively regulated the activity of mTORC1 with consequent autophagy
inhibition. apoA-I, apolipoprotein A-I; HDL, high density lipoprotein; PI3K, phosphatidylinositol 3-kinase; S1P, sphingosine-1-phosphate.
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sistently, HDL stimulated glucose uptake in 3T3-L1 adi-
pocytes involving PI3K-Akt activation via SR-B1.
Knocking-down SR-B1 with RNA interference lead to di-
minish of glucose uptake stimulated by HDL with con-
sistent pronounced inhibition of Akt activation [74].
Apart from SR-B1, sphingosine-1-phosphate (S1P)
receptors binding with S1P of HDL has also been
demonstrated to mediate PI3K-Akt signaling in mice
myocardiocyte. A recent study demonstrated that HDL
applied directly to isolated adult mouse cardiomyocytes
enhances cell survival during hypoxia-reoxygenaration
through stimulating signal PI3K-Akt. The prosurvival
signal is mediated by S1P3 (sphingosine 1-phosphate 3)
receptors located on the myocyte and are markedly atte-
nuated by inhibitors of these receptors [71]. Taken to-
gether, HDL may activate PI3K-Akt signaling through
SR-BI and S1P receptor (Figure 2).
Conclusion
Obesity, especially central obesity, is risk factor of cardio-
vascular disease and type 2 diabetes mellitus. Attainment
of phenotype resembling brown adipocyte in WAT could
reduce adipose deposit through enhanced β-oxidation.
Inhibiting autophagy in adipose tissue leads white adi-
pocyte to acquire features of brown adipocyte, there-
fore exerting an anti-obesity effect and improving
obesity associated insulin sensitivity. Taken that HDL
and apoA-I has direct anti-obesity effect in rat and that
HDL activate PI3K-Akt signaling which negatively regu-
late autophagy through mTORC1, we propose that HDL/
apoA-I inhibit autophagy through PI3K-Akt signaling,
leading to phenotype transition of white adipocyte. This
new link between HDL/apoA-I and autophagy provide anew understanding of the possible mechanism underline
the antiobesity effect of HDL/apoA-I.
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